Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India.
Health Policy Plan. 2013 Jan; 28(1):51-61.HP

Abstract

OBJECTIVE

In India, Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization programme requires evidence of its potential health impact and cost-effectiveness, as it is a costly vaccine. Since childhood mortality, vaccination coverage and health service utilization vary across states, the cost-effectiveness of introducing Hib vaccine was studied in Haryana state.

METHODOLOGY

A mathematical model was used to compare scenarios with and without Hib vaccination to estimate the cost-effectiveness of Hib vaccine in Haryana from 2010 to 2024. Demographic and National Family Health Surveys were used to estimate vaccination coverage and mortality rates among children under 5. Hib pneumonia, Hib meningitis and invasive Hib disease incidence were based on Indian studies. Vaccine and syringe prices of the UNICEF supply division were used. Cost-effectiveness from government and societal perspectives was calculated as the net incremental cost per unit of health benefit gained [disability-adjusted life years (DALYs) averted, life years saved, Hib cases averted, Hib deaths averted]. Sensitivity analysis was done using variation in parameter estimates among different states of India.

FINDINGS

The incremental cost of Hib vaccine introduction from a government and a societal perspective was estimated to be US$81.4 and US$27.5 million, respectively, from 2010 to 2024. Vaccination of 73.3, 71.6 and 67.4 million children with first, second and third dose of pentavalent vaccine, respectively, would avert 7 067 817 cases, 31 331 deaths and 994 564 DALYs. Incremental cost per DALY averted from a government (US$819) and a societal perspective (US$277) was found to be less than the per capita gross national income of India in 2009. In sensitivity analysis, Hib vaccine introduction remained cost-effective for India.

CONCLUSION

Hib vaccine introduction is a cost-effective strategy in India.

Authors+Show Affiliations

School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India. madhugupta21@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22407018

Citation

Gupta, Madhu, et al. "Cost-effectiveness of Haemophilus Influenzae Type B (Hib) Vaccine Introduction in the Universal Immunization Schedule in Haryana State, India." Health Policy and Planning, vol. 28, no. 1, 2013, pp. 51-61.
Gupta M, Prinja S, Kumar R, et al. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy Plan. 2013;28(1):51-61.
Gupta, M., Prinja, S., Kumar, R., & Kaur, M. (2013). Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy and Planning, 28(1), 51-61. https://doi.org/10.1093/heapol/czs025
Gupta M, et al. Cost-effectiveness of Haemophilus Influenzae Type B (Hib) Vaccine Introduction in the Universal Immunization Schedule in Haryana State, India. Health Policy Plan. 2013;28(1):51-61. PubMed PMID: 22407018.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. AU - Gupta,Madhu, AU - Prinja,Shankar, AU - Kumar,Rajesh, AU - Kaur,Manmeet, Y1 - 2012/03/08/ PY - 2012/3/13/entrez PY - 2012/3/13/pubmed PY - 2013/12/16/medline SP - 51 EP - 61 JF - Health policy and planning JO - Health Policy Plan VL - 28 IS - 1 N2 - OBJECTIVE: In India, Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization programme requires evidence of its potential health impact and cost-effectiveness, as it is a costly vaccine. Since childhood mortality, vaccination coverage and health service utilization vary across states, the cost-effectiveness of introducing Hib vaccine was studied in Haryana state. METHODOLOGY: A mathematical model was used to compare scenarios with and without Hib vaccination to estimate the cost-effectiveness of Hib vaccine in Haryana from 2010 to 2024. Demographic and National Family Health Surveys were used to estimate vaccination coverage and mortality rates among children under 5. Hib pneumonia, Hib meningitis and invasive Hib disease incidence were based on Indian studies. Vaccine and syringe prices of the UNICEF supply division were used. Cost-effectiveness from government and societal perspectives was calculated as the net incremental cost per unit of health benefit gained [disability-adjusted life years (DALYs) averted, life years saved, Hib cases averted, Hib deaths averted]. Sensitivity analysis was done using variation in parameter estimates among different states of India. FINDINGS: The incremental cost of Hib vaccine introduction from a government and a societal perspective was estimated to be US$81.4 and US$27.5 million, respectively, from 2010 to 2024. Vaccination of 73.3, 71.6 and 67.4 million children with first, second and third dose of pentavalent vaccine, respectively, would avert 7 067 817 cases, 31 331 deaths and 994 564 DALYs. Incremental cost per DALY averted from a government (US$819) and a societal perspective (US$277) was found to be less than the per capita gross national income of India in 2009. In sensitivity analysis, Hib vaccine introduction remained cost-effective for India. CONCLUSION: Hib vaccine introduction is a cost-effective strategy in India. SN - 1460-2237 UR - https://www.unboundmedicine.com/medline/citation/22407018/Cost_effectiveness_of_Haemophilus_influenzae_type_b__Hib__vaccine_introduction_in_the_universal_immunization_schedule_in_Haryana_State_India_ L2 - https://academic.oup.com/heapol/article-lookup/doi/10.1093/heapol/czs025 DB - PRIME DP - Unbound Medicine ER -